Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study Wu, Y., Mok, T., Reck, M., Wakelee, H., Liang, C., Tan, F., Harrow, K., Oertel, V., Dukart, G., Ding, L., Horn, L. ELSEVIER SCIENCE INC. 2017: S2402
View details for DOI 10.1016/j.jtho.2017.11.025
View details for Web of Science ID 000463860802561